Singapore, June 22 -- Chime Biologics, a global biologics contract development and manufacturing organisation (CDMO), has announced the inauguration of its GMP-2 manufacturing facility in Wuhan, China, further expanding its capacity to support growing global demand for biologics.

The new facility is equipped with eight 2,000-liter single-use Xcellerex bioreactors from Cytiva, a Danaher company and a leader in the life sciences industry, providing flexible and efficient capacity to support scale-up from discovery to delivery, while maintaining consistent quality.

This latest expansion builds on a decade of collaboration between Cytiva and Chime Biologics. The company's first manufacturing facility was built using the KUBio modular manufa...